Abstract
Satralizumab (Enspryng(R)) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of neuromyelitis o......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
